%0 Journal Article %T Chemotherapy versus tyrosine kinase inhibitor in EGFR unselected population advanced non-small cell lung cancer still matter of debate?—An update incorporating the DELTA trial data %A Garassino, Marina C. %A Broggini, Massimo %J Journal of Thoracic Disease %D 2015 %B 2015 %9 %! Chemotherapy versus tyrosine kinase inhibitor in EGFR unselected population advanced non-small cell lung cancer still matter of debate?—An update incorporating the DELTA trial data %K %X At present, for the treatment of second line advanced nonsmall cell lung cancer (NSCLC), three drugs are now available, pemetrexed, docetaxel and erlotinib (1-3). Docetaxel was registered in a superiority trial over placebo and it became the first second line approved at the beginning of this century, while erlotinib was licensed with a pivotal trial against placebo five years later (2). %U https://jtd.amegroups.org/article/view/4073 %V 7 %N 3 %P 224-226 %@ 2077-6624